188 related articles for article (PubMed ID: 31591016)
1. Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity.
Zhang Z; Banerjee M; Davis RE; Blagg BSJ
Bioorg Med Chem Lett; 2019 Nov; 29(22):126676. PubMed ID: 31591016
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antiproliferative activity of 6BrCaQ-TPP conjugates for targeting the mitochondrial heat shock protein TRAP1.
Mathieu C; Chamayou Q; Hyen Luong TT; Naud D; Mahuteau-Betzer F; Alami M; Fattal E; Messaoudi S; Vergnaud-Gauduchon J
Eur J Med Chem; 2022 Feb; 229():114052. PubMed ID: 34952432
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.
Byrd KM; Subramanian C; Sanchez J; Motiwala HF; Liu W; Cohen MS; Holzbeierlein J; Blagg BS
Chemistry; 2016 May; 22(20):6921-31. PubMed ID: 27037933
[TBL] [Abstract][Full Text] [Related]
4. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer.
Forsberg LK; Liu W; Holzbeierlein J; Blagg BSJ
Bioorg Med Chem Lett; 2017 Sep; 27(18):4514-4519. PubMed ID: 28844386
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors.
Garg G; Zhao H; Blagg BS
Bioorg Med Chem; 2017 Jan; 25(2):451-457. PubMed ID: 27914946
[TBL] [Abstract][Full Text] [Related]
6. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
Burlison JA; Avila C; Vielhauer G; Lubbers DJ; Holzbeierlein J; Blagg BS
J Org Chem; 2008 Mar; 73(6):2130-7. PubMed ID: 18293999
[TBL] [Abstract][Full Text] [Related]
7. Mitochondria-Targeted Triphenylphosphonium Conjugated C-3 Modified Betulin: Synthesis, Antitumor Properties and Mechanism of Action.
Xu G; Xu X; Liu J; Jia Q; Ke C; Zhang H; Xu C; Ou E; Tan W; Zhao Y
ChemMedChem; 2022 Feb; 17(4):e202100659. PubMed ID: 34881517
[TBL] [Abstract][Full Text] [Related]
8. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors.
Jiang F; Guo AP; Xu JC; Wang HJ; Mo XF; You QD; Xu XL
Eur J Med Chem; 2017 Dec; 141():1-14. PubMed ID: 29028527
[TBL] [Abstract][Full Text] [Related]
9. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.
Zhao H; Anyika M; Girgis A; Blagg BS
Bioorg Med Chem Lett; 2014 Aug; 24(15):3633-7. PubMed ID: 24953820
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.
Byrd KM; Kent CN; Blagg BSJ
ChemMedChem; 2017 Dec; 12(24):2022-2029. PubMed ID: 29058824
[TBL] [Abstract][Full Text] [Related]
11. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors.
Garg G; Forsberg LK; Zhao H; Blagg BSJ
Chemistry; 2017 Nov; 23(65):16574-16585. PubMed ID: 28940589
[TBL] [Abstract][Full Text] [Related]
12. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.
Zhao H; Donnelly AC; Kusuma BR; Brandt GE; Brown D; Rajewski RA; Vielhauer G; Holzbeierlein J; Cohen MS; Blagg BS
J Med Chem; 2011 Jun; 54(11):3839-53. PubMed ID: 21553822
[TBL] [Abstract][Full Text] [Related]
13. Novobiocin Analogues That Inhibit the MAPK Pathway.
Hall JA; Seedarala S; Zhao H; Garg G; Ghosh S; Blagg BS
J Med Chem; 2016 Feb; 59(3):925-33. PubMed ID: 26745854
[TBL] [Abstract][Full Text] [Related]
14. Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues.
Peterson LB; Blagg BS
Bioorg Med Chem Lett; 2010 Jul; 20(13):3957-60. PubMed ID: 20570149
[TBL] [Abstract][Full Text] [Related]
15. Novobiocin-ferrocene conjugates possessing anticancer and antiplasmodial activity independent of HSP90 inhibition.
Mbaba M; de la Mare JA; Sterrenberg JN; Kajewole D; Maharaj S; Edkins AL; Isaacs M; Hoppe HC; Khanye SD
J Biol Inorg Chem; 2019 Mar; 24(2):139-149. PubMed ID: 30542925
[TBL] [Abstract][Full Text] [Related]
16. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
[TBL] [Abstract][Full Text] [Related]
17. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
[TBL] [Abstract][Full Text] [Related]
19. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1.
Lee C; Park HK; Jeong H; Lim J; Lee AJ; Cheon KY; Kim CS; Thomas AP; Bae B; Kim ND; Kim SH; Suh PG; Ryu JH; Kang BH
J Am Chem Soc; 2015 Apr; 137(13):4358-67. PubMed ID: 25785725
[TBL] [Abstract][Full Text] [Related]
20. Mitochondria-Targeted Lupane Triterpenoid Derivatives and Their Selective Apoptosis-Inducing Anticancer Mechanisms.
Ye Y; Zhang T; Yuan H; Li D; Lou H; Fan P
J Med Chem; 2017 Jul; 60(14):6353-6363. PubMed ID: 28671831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
